Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins

19 August 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract


Targeted protein degradation (TPD) technology has drawn significant attention from researchers in both academia and industry. It is rapidly evolved as a new therapeutic modality and also a useful chemical tool in selectively depleting various protein targets. As most efforts focus on cytosolic proteins using PROteolysis TArgeting Chimera (PROTAC), LYsosome TArgeting Chimera (LYTAC) recently emerged as a promising technology to deliver extracellular protein targets to lysosome for degradation through cation-independent mannose-6-phosphate receptor (CI-M6PR). In this study, we exploited the potential of asialoglycoprotein receptor (ASGPR), a lysosomal targeting receptor specifically expressed on liver cells, for the degradation of extracellular proteins. The ligand of ASGPR, triantennary N-acetylgalactosamine (tri-GalNAc), was conjugated to biotin, antibodies, or fragments of antibodies to generate a new class of degraders. We demonstrated that the extracellular protein targets could be successfully internalized and delivered into lysosome for degradation in a liver cell line specifically by these degraders. We also observed that more efficient delivery could be achieved for smaller degrader/target complexes. This work will add a new dimension to the TPD with cell type specificity.

Keywords

targeted protein degradation
degraders
asialoglycoprotein receptor
N-acetylgalactosamine
PROTAC
LYTAC

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.